Ulrich Steidl, MD, Ph.D

​Ulrich Steidl, M.D, Ph.D., trained as a postdoctoral researcher at Harvard Medical School prior to joining the Albert Einstein College of Medicine as faculty in 2008, where he currently holds appointments as Professor and Chair of the Department of Cell Biology, as well as Professor of Oncology, and of Medicine. Ulrich Steidl also serves as the Deputy Director of the NCI-designated Montefiore-Einstein Comprehensive Cancer Center, as well as the Interim Director of the Ruth L. and David S. Gottesman Institute for Stem Cell Research and Regenerative Medicine. Dr. Steidl’s work has pioneered mechanistic studies and target identification in pre-cancerous and leukemia stem cells, as well as myeloid fate decision making in hematopoietic stem cells, and his work has led to numerous patents, drug development efforts, and clinical trials. Dr. Steidl has served as an advisor to many large pharma and small/midsize biotech companies and has been a scientific co-founder of Stelexis BioSciences.

He received his MD and Ph.D from the University of Heidelberg Medical School, and German Cancer Research Center (DKFZ).